Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Antibody reduces harmful brain amyloid plaques in Alzheimer's patients

Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer’s disease. Read & Research Alzheimer’s More

Leave a Reply